Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction

Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction

Understanding the underlying molecular mechanisms behind ADE of SARS-CoV-2 is critical for development of safe and effective therapies. Here, we report that two neutralizing mAbs, MW01 and MW05, could enhance the infection of SARS-CoV-2 pseudovirus on FcγRIIB-expressing B cells. X-ray crystal struct...

Full description

Bibliographic Details
Main Authors:	Chen, B. (Author), Chen, H. (Author), Chen, S. (Author), Gu, C. (Author), Gui, X. (Author), Guo, C. (Author), Jiang, W. (Author), Jiao, S. (Author), Li, G. (Author), Liu, C. (Author), Liu, D. (Author), Wang, A. (Author), Wang, J. (Author), Wang, L. (Author), Wang, M. (Author), Wang, R. (Author), Wang, S. (Author), Wang, W. (Author), Yang, Y. (Author), Yu, X. (Author), Zhang, J. (Author), Zhang, M. (Author)
Format:	Article
Language:	English
Published:	Nature Research 2022
Subjects:	Antibodies, Viral antibody dependent enhancement Antibody-Dependent Enhancement coronavirus spike glycoprotein COVID-19 human Humans SARS-CoV-2 Spike Glycoprotein, Coronavirus spike protein, SARS-CoV-2 virus antibody
Online Access:	View Fulltext in Publisher

Similar Items

Anti-Receptor-Binding Domain Immunoglobulin G Antibody as a Predictor of Seropositivity for Anti-SARS-CoV-2 Neutralizing Antibody
by: Li, Q.-L, et al.
Published: (2022)

Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage
by: Amoako, D.G, et al.
Published: (2022)

Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage
by: Amoako, D.G, et al.
Published: (2022)

Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit
by: Andrabi, R., et al.
Published: (2022)

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset
by: Sai Priya Anand, et al.
Published: (2021-06-01)

Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
by: Natalie Yan-Lin Pang, et al.
Published: (2021-08-01)

Extracellular vesicles carry SARS‐CoV‐2 spike protein and serve as decoys for neutralizing antibodies
by: Zach Troyer, et al.
Published: (2021-06-01)

Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2
by: Jie Hu, et al.
Published: (2020-12-01)

Dynamic Characteristic Analysis of Antibodies in Patients With COVID-19: A 13-Month Study
by: Danrong Shi, et al.
Published: (2021-07-01)

Development of Coronavirus Treatments Using Neutralizing Antibodies
by: Saman Fouladirad, et al.
Published: (2021-01-01)

Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies
by: Maxwell T. Finkelstein, et al.
Published: (2021-01-01)

Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies
by: Joe James, et al.
Published: (2021-04-01)

Neutralizing antibodies targeting SARS-CoV-2 spike protein
by: Shi Xiaojie, et al.
Published: (2021-01-01)

Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines
by: Jianhua Li, et al.
Published: (2021-05-01)

Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses
by: Luca Vangelista, et al.
Published: (2020-09-01)

An Overview of Spike Surface Glycoprotein in Severe Acute Respiratory Syndrome–Coronavirus
by: Muthu Kumaradoss Kathiravan, et al.
Published: (2021-03-01)

Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients
by: Mehul S. Suthar, et al.
Published: (2020-06-01)

Lack of MERS Coronavirus Neutralizing Antibodies in Humans, Eastern Province, Saudi Arabia
by: Stefanie Gierer, et al.
Published: (2013-12-01)

Serum Levels of Proinflammatory Lipid Mediators and Specialized Proresolving Molecules Are Increased in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 and Correlate With Markers of the Adaptive Immune Response
by: Barrett, D.A, et al.
Published: (2022)

The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic
by: Priyanka Shah, et al.
Published: (2021-03-01)

Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma
by: Thomas P. Thomopoulos, et al.
Published: (2021-09-01)

Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset
by: Tiandan Xiang, et al.
Published: (2021-06-01)

Binding affinity and mechanisms of SARS-CoV-2 variants
by: Yanqiang Han, et al.
Published: (2021-01-01)

Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen
by: Min Jiang, et al.
Published: (2021-09-01)

Comprehensive analysis of SARS‐CoV‐2 antibody dynamics in New Zealand
by: Alana L Whitcombe, et al.
Published: (2021-01-01)

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
by: Federico Bertoglio, et al.
Published: (2021-07-01)

SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia
by: Wei Chen, et al.
Published: (2020-10-01)

Therapeutic Potential of Glycosyl Flavonoids as Anti-Coronaviral Agents
by: Patrícia I. C. Godinho, et al.
Published: (2021-06-01)

Establishment of Murine Hybridoma Cells Producing Antibodies against Spike Protein of SARS-CoV-2
by: Nadezhda V. Antipova, et al.
Published: (2020-12-01)

Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2
by: Rocktotpal Konwarh, et al.
Published: (2020-06-01)

Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals
by: Etienne Brochot, et al.
Published: (2020-10-01)

Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China
by: Xia Feng, et al.
Published: (2021-03-01)

A newly identified linear epitope on non-RBD region of SARS-CoV-2 spike protein improves the serological detection rate of COVID-19 patients
by: Yunwen Zhang, et al.
Published: (2021-06-01)

Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
by: Elaine C. Chen, et al.
Published: (2021-08-01)

Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope
by: Efi Makdasi, et al.
Published: (2021-03-01)

Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike
by: Jérémie Prévost, et al.
Published: (2020-10-01)

A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2
by: Xiaojian Han, et al.
Published: (2021-03-01)

Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control
by: Cheryl Yi-Pin Lee, et al.
Published: (2020-04-01)

Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis
by: Margherita Passariello, et al.
Published: (2021-08-01)

Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins
by: Sai Priya Anand, et al.
Published: (2020-09-01)